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Abstract 
Background: Polyhexamethylene guanidine phosphate (PHMG-P) belongs to the polymeric guanidine family of bio-
cides and contains a phosphate group, which may confer better solubility, a detoxifying effect and may change the 
kinetics and dynamics of PHMG-P interactions with microorganisms. Limited data regarding PHMG-P activity against 
periodontopathogenic and cariogenic microorganisms necessitates studies in this area. Aim is to evaluate polyhexa-
methylene guanidine phosphate antimicrobial activity in comparison to chlorhexidine.
Methods: Quantitative suspension method was used enrolling Staphylococcus aureus, Pseudomonas aeruginosa, 
Escherichia coli and Candida albicans, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Streptococcus 
mutans and Lactobacillus acidophilus.
Results: Both tested antiseptics at their clinically-used concentrations, of 0.2% (w/v) and 1% (w/v), correspond-
ingly provided swift bactericidal effects against S. aureus, P. aeruginosa, E. coli and C. albicans, A. actinomycetemcomi-
tans and P. gingivalis with reduction factors higher than 6.0. Diluted polyhexamethylene guanidine phosphate and 
chlorhexidine to 0.05% continued to display anti-bacterial activity and decreased titers of standard quality control, 
periopathogens to below 1.0 × 103 colony forming units/ml, albeit requiring prolonged exposure time. To achieve a 
bactericidal effect against S. mutans, both antiseptics at all concentrations required a longer exposure time. We found 
that a clinically-used 1% of polyhexamethylene guanidine phosphate concentration did not have activity against L. 
acidophilus.
Conclusion: High RF of polyhexamethylene guanidine phosphate and retention of bactericidal effects, even at 
0.05%, support the use of polyhexamethylene guanidine phosphate as a biocide with sufficient anti-microbial activity 
against periopathogens. Polyhexamethylene guanidine phosphate displayed bactericidal activity against periopatho-
gens and S. mutans and could potentially be applied in the management of oral diseases.
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Background
Dental plaque, is a biofilm that is recognized as a 
cause and significant risk factor for periodontal dis-
eases [1]. The imbalance in non-pathogenic biofilm 
auto-regulation, behavioral aspects and immunological 
reactivity of the host results in maximizing the patho-
logical potential of dental plaque with the accumulation 
of periopathogens, and an increased risk of periodontal 
disease. The pathogenic nature of the dental biofilm can 
be diminished in the oral cavity by reducing the biobur-
den and effectively maintaining a normal oral flora via 
oral hygiene routines (daily toothbrushing and flossing) 
and treatment procedures (scaling and root planning) 
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[2, 3]. To enhance the efficacy of periodontal treatment, 
locally delivered anti-microbials have become an essen-
tial component of anti-infective management of peri-
odontal diseases and has stimulated the development of 
state-of-the-art antiseptics for local application to mod-
ify biofilm composition, and re-establish dental biofilm 
autoregulation [4]. Mature biofilm shows a higher toler-
ance for anti-microbial agents [5]. Thus, it has been sug-
gested that minimal inhibitory concentrations should be 
determined for bacteria as part of a biofilm and not in 
the planktonic state [6]. However, currently there is lack 
of standardized methods to perform this type of assess-
ment [7]. The properties of the biofilm can differ depend-
ing on the environment on which it forms. For example, 
Acinetobacter baumannii has different resistance profiles 
in laboratory media versus on ex vivo human ascites [8].
A considerable amount of research has concentrated 
on evaluating cellular toxicity and bacterial activity of 
topical anti-microbials to derive arrays of biocompatible 
antiseptics that can be exploited in dentistry for anti-
infective management of periodontal diseases. Selection 
of antiseptics is based on their specificity, efficacy, sub-
stantivity, safety, stability and plaque control. Of the mis-
cellaneous antiseptics, chlorhexidine (CHX) has acquired 
a widespread and successful application in dentistry and 
has been considered the golden standard for many years 
[9]. Some adverse effects of CHX, include tooth and 
tongue staining, changes in taste, desquamation of the 
mucosa membrane in the oral cavity, a dose dependent 
reduction in collagen or non-collagenous protein pro-
duction by gingival fibroblasts, and a reduction in their 
proliferation [10]. These have given an impetus for the 
development new antiseptics without adverse effects for 
administration in dentistry.
Polyhexamethyleneguanidine (PHMG) derivates are 
members of the polymeric guanidine family that have 
been widely used for many years as antiseptics in medi-
cine and the food industry [11]. Detoxified conjugates of 
polyhexamethylene biguanide hydrochloride (PHMB-H) 
and polyhexamethylene guanidine phosphate (PHMG-P) 
with incorporated different anions are highly soluble in 
water [12]. PHMB-H has been extensively tested in vivo 
and in  vitro [11, 13–15]. Clinical studies have shown 
that PHMB-H mouthwash consistently inhibits plaque 
regrowth and reduces oral bacterial counts, indicating 
that PHMB-H could be an alternative active substance of 
dentifrices. Data regarding specificity, efficacy, substan-
tivity, safety, stability and plaque control of PHMG-P are 
unavailable and its efficacy in the treatment of periodon-
tal diseases and activity against periodontopathogenic 
and cariogenic bacteria requires evaluation. Following 
antiseptic administration in the oral cavity, over time 
antiseptics are gradually diluted in the saliva and their 
activity decreases from the start of treatment [16]. There-
after, antiseptics even at low concentrations are able to 
continue exerting effects until inactivation. Therefore, 
anti-microbial activity should be tested not only on the 
clinically-used working concentration but on several 
dilutions with different exposure times.
In this study the bactericidal effects of PHMG-P have 
been studied on planktonic forms of standard bacterial 
species along with cariogenic and periodontopathogenic 
bacteria to evaluate its feasibility in the management 
of carries and periodontal diseases. The aim of this 
study was to evaluate the prospective of application of 
PHMG-P based antiseptics in dentistry by comparing 
PHMG-P anti-microbial activity against periopathogenic, 
cariogenic and standard quality control microorganisms 
to CHX using the quantitative suspension method.
Methods
Bacterial strains and cultivation
Anti-bacterial activity of antiseptics was estimated on 
the following standard strains of Staphylococcus aureus 
(ATCC 6538), Escherichia coli (ATCC 11229), Pseu-
domonas aeruginosa (ATCC 15412), and Candida albi-
cans (ATCC 1023), and on the oral Gram-negative 
periodontal pathogens Porphyromonas gingivalis (ATCC 
33277), Aggregatibacter actinomycetemcomitans (HK 
1519), Gram-positive cariogenic strains Streptococcus 
mutans (CCUG 27624; Ing-Brit), and Lactobacillus aci-
dophilus (NCTC 1723). The strains of S. aureus, E. coli, P. 
aeruginosa and C. albicans were inoculated on trypticase 
soy agar (TSA) (Becton–Dickinson, NJ, USA) and incu-
bated for 18–24 h at 37°C. The number of these micro-
organisms suspended in sterile phosphate buffered saline 
(PBS) was adjusted by detection of optical (OD) density 
and determined precisely by the drop count method. 
P. gingivalis was cultured on Colombia base agar (Acu-
media, Baltimore, MD, USA) supplemented with hemin 
(0.05  mg/ml) (Sigma-Aldrich, Sweden AB), vitamin K 
(0.01  mg/ml) (BBL™, Becton–Dickinson), and citrated 
horse blood (5%) (Sigma-Aldrich), in anaerobic atmos-
phere (GasPak, Becton–Dickinson) for 7  days. The 
test-suspension of P. gingivalis with OD 0.73–0.75 was 
prepared in peptone yeast glucose broth (Becton–Dick-
inson). Two days culture of A. actinomycetemcomitans 
grown on Colombia base agar supplemented with 0.01% 
tryptophan and citrated horse blood (5%) was suspended 
in haemophilus teat medium (HTM) broth (Bacto™, 
Becton–Dickinson). OD of the suspension was adjusted 
to 0.76–0.78. S. mutans were cultured on brain heart 
infusion (BHI) (Oxoid, Malmö, Sweden) agar for 2 days 
and a suspension with an OD of 0.14 was prepared in 
BHI broth. L. acidophilus was cultured on Lactobacilli 
MRS (de Man, Rogosa and Sharpe) medium (Difco™, 
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Becton–Dickinson) for 2 days and a test-suspension with 
an OD of 0.14–0.15 was prepared in Lactobacilli MRS 
broth. The reference strains of S. mutans, A. actinomy-
cetemcomitans, L. acidophilus were cultured in capno-
philic atmosphere containing 5% CO2. The turbidity of 
all suspensions was standardized for each bacterial strain 
using a spectrophotometer at 580  nm (Biochrom WPA 
CO7500 Colorwave Colorimeter), to provide the concen-
tration of test-microorganisms approximately equal to 
1 ×  108 colony-forming unit/ml (CFU/ml). All bacteria 
were filtered through 5  μm (Pall Corporation, USA) to 
provide better separation.
Antiseptics
A working concentration of PHMG-P 1% (w/v), typically 
used in the clinic setting, and dilutions 0.5, 0.2, 0.05% 
(w/v) were prepared ex tempore in dH2O from concen-
trated 70% PHMG-P gel, with an average molecular 
weight of 4,000–9,000 (Institute of Eco-Technological 
Problems, Moscow, Russia). Anti-microbial activity of 
PHMG-P was tested in comparison to 0.05, 0.2, 0.5, 1% 
(w/v) CHX prepared from 1% CHX (Apotek Produktion 
and Laboratorier AB, Stockholm, Sweden). Each concen-
tration of antiseptic (PHMG-P and CHX) was exposed 
for 30 s, 1, 3, and 5 min, respectively. Hydrogen peroxide 
(H2O2) 3% (w/v) was included, as a control for a product 
with known efficacy.
Neutralizing solution
Neutralizing solution, encompassing 1% (w/v) peptone, 
3% (w/v) Tween 80 (BDH, Poole, UK), 0.3% (w/v) lecithin 
(Fisher Scientific, Loughborough, UK), 0.1% (w/v) histi-
dine (BDH) and 0.1% (w/v) cysteine (Sigma-Aldrich) was 
prepared in dH2O and sterilized.
Bactericidal activity evaluation
Bactericidal activity of anti-microbials was tested by 
using the quantitative suspension method according to 
European standards EN 1040:2005 CSN EN 1040 at room 
temperature. Briefly, 50  μl of the test-suspensions of 
microorganisms with an OD of 1.0 × 108 CFU/ml were 
exposed to 450 μl of each antiseptic (PHMG-P, CHX or 
H2O2) at concentrations of 0.05, 0.2, 0.5, and 1% for 30 s, 
1, 3 and 5  min, followed by transfer of the mixture to 
450 μl neutralizer. After neutralization for 10 min a serial 
dilution (10−3, 10−4, and 10−5) was performed and 100 μl 
aliquots were plated on appropriate media and incubated 
at 37°C for 2–7  days for respective bacteria. Colonies 
were counted and the viability of the test mixture calcu-
lated. Anti-bacterial properties of neutralizing solution 
to test-microorganisms were controlled. Activity of anti-
septics was evaluated by reduction factor (RF) that was 
calculated as the difference between logarithms of CFU/
ml before and after exposure to tested concentrations 
of antiseptics. Sensitivity threshold of the method was 
considered as 1.0 × 103 CFU/ml of bacteria. If the anti-
septic led to total loss of bacteria, defined as no bacterial 
growth, it was assigned as ≤1.0 ×  103  CFU/ml. Detec-
tion of bactericidal effect of the antiseptic agents against 
test species was performed on two separate occasions in 
duplicate, for each product and each exposure time.
Activity of PGMG-P versus CHX was evaluated on the 
basis of observed bactericidal effect resulting in a total 
loss of bacteria and a titer beneath 1.0  ×  103  CFU/ml. 
Such pairwise comparison did not allow for the estima-
tion of difference in CFU number.
Results
Activity of CHX and PHMG‑P against standard 
quality‑control microorganisms
Anti-microbial properties of PHMG-P were tested in 
comparison with CHX against quality-control strains 
of S. aureus, P. aeruginosa, E. coli, C. albicans. Results 
are summarized in Figures  1, 2, and Additional file  1: 
Table S1.
Anti-microbial action of clinically-relevant working 
concentrations of PHMG-P (1%) and CHX (0.2%) against 
standard quality control microorganisms (S. aureus, E. 
coli, P. aeruginosa and C. albicans) exhibited a very simi-
lar pattern of activity (Figure  1). 1% PHMG-P and 0.2% 
CHX expressed rapid bactericidal effects on all species 
within 30  s of action and decreased the bacterial titer 
below 1.0 × 103 CFU/m (RF over 5).
Both 0.05% diluted PHMG-P and CHX (20-fold) were 
unable to eliminate S. aureus over 30  s exposure and 
led to a reduction of bacterial titer from 1.47  ×  109 to 
1.8 × 104 CFU/ml and from 2.0 × 109 to 3.0 × 105 CFU/
ml, respectively (Figure  2). Prolonged biocide exposure 
for 3  min caused a strong bactericidal effect, accom-
panied by a falling microbial titer below the sensitivity 
threshold.
Application of 0.05% PHMG-P and 0.05% CHX for 
30  s decreased the E. coli population from 2.17  ×  109 
to 2.0 ×  105  CFU/ml (RF 4.04), and from 2.7  ×  109 to 
4.0  ×  103  CFU/ml, respectively, whilst increased treat-
ment time to 3 min resulted in total eradication of bacte-
ria (RF 6.48 and 6.41 correspondingly) (Figure 2).
Only extended exposure of P. aeruginosa for 3  min at 
0.05% PHMG-P resulted in a full bacteria elimination 
(RF 6.07), however bactericidal activity against P. aerugi-
nosa with 0.05% CHX required 5 min exposure (RF 6.0) 
(Figure 2).
Application of 0.05% PHMG-P and 0.05% CHX for 30 s 
exposure to C. albicans did not produce any significant 
anti-candidal effect and reduced fungal population from 
3.77 × 108 to 1.0 × 106 CFU/ml and from 8.0 × 108 to 
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1.0 × 106 CFU/ml, respectively (Figure 2). 0.05% PHMG-
P eliminated C. albicans within 3 min, whilst 0.05% CHX 
decreased the amount of fungi below 1.0 × 103 CFU/ml 
only after longer treatment period (5 min).
Activity of CHX and PHMG‑P against perio‑ and cariogenic 
microorganisms
The results of antimicrobial activity of antiseptics against 
periopathogenic and cariogenic microorganisms are 
shown in Figures 3, 4, and Additional file 2: Table S2.
1.0% PHMG-P and 0.2% CHX, clinically-relevant work-
ing concentrations, effectively inhibited periopathogens 
(A. actinomycetemcomitans and P. gingivalis) (Figure  3), 
displaying swift activity within 30  s of exposure with a 
decrease in microbial titers less than 1 × 103 CFU/ml, for 
each periopathogen resulting in RF’s over 6.06 and 5.86, 
respectively.
Evaluation of 1% PHMG-P and 0.2% CHX bacteri-
cidal activity against S. mutans indicated that tested 
concentrations of antiseptics after 30  s exposure did 
not result in any significant reduction in the concentra-
tion of S. mutans, with RF’s equaling 2.3 and 3.88 (Fig-
ure 3). Following an extended treatment time (3–5 min), 
the working concentration of PHMG-P (1%) and CHX 
(0.2%) completely inhibited S. mutans. Thus, the titer of 
these cariogenic microorganisms also fell from below 
1 × 103 CFU/ml (RF’s 5.8 and 5.73).
Highly diluted PHMG-P and CHX (0.05%) acting for 
30 s exhibited a milder influence against A. actinomycet-
emcomitans and P. gingivalis, characterized by RF’s lower 
than 4 (Figure  4). Extending antiseptic treatment for 
3  min resulted in total bacteria elimination (RF ≥  5.86) 
for both reagents.
PHMG-P and CHX at concentrations of 0.05% over 
30 s caused only a minor fall in microbial concentration 
of L. acidophilus, with RF values 0.24 and 0.51, respec-
tively (Figure  4). Increased antiseptic concentrations of 
1% PHMG-P and 0.2% CHX after 5 min exposure failed 
to produce a bactericidal effect (Figure 3). The RF value 
of PHMG-P with respect to L. acidophilus varied in the 
Figure 1 Anti-microbial activity of clinical working concentrations of PHMG-P (1%) and CHX (0.2%) against standard quality control microorgan-
isms (S. aureus, E. coli, P. aeruginosa and C. albicans).
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range of 0.12–0.43 suggesting extremely low anti-bacte-
rial activity. However, CHX expressed higher anti-micro-
bial activity against L. acidophilus and at concentrations 
of 0.5% for 5  min resulted in total bacteria eradication 
(RF 4.1). Unlike periopathogens, stricter PHMG-P and 
CHX application modes were required to control L. aci-
dophilus cell titers below 1.0 × 103 CFU/ml.
In the present study, PHMG-P and CHX at 0.05% for 
30  s displayed only limited anti-microbial impact on S. 
mutans, illustrated by the respective RF values of 0.28 
and 0.99, respectively (Figure  3). 0.05% PHMG-P and 
0.05% CHX over 3  min also demonstrated insufficient 
anti-microbial activity (RF 3.55 and 3.73 correspond-
ently), when extended to 5  min treatment, a reduced 
amount of S. mutans below the methods sensitivity 
threshold (≤1 × 103 CFU/ml) was obtained.
3% H2O2 eliminated S. aureus, E. coli and P. aer-
uginosa within 30  s of exposure time (RF’s  ≤  6.29). 
Prolonged biocide exposure for 5  min was required 
for H2O2 to eradicate C. albicans (RF 5.42). In addi-
tion, control of neutralization confirmed absence of 
anti-bacterial effect of neutralizer on bacteria since no 
fall CFU/ml was registered after neutralization (data 
not shown).
Discussion
Comparative anti-microbial activity of antiseptic agents 
using suspension-based methods, broth or agar dilution 
have been evaluated in many studies and the data regard-
ing anti-bacterial efficacy of antiseptics are contradictive 
[15, 17, 18]. In clinical studies, concentrations of 0.04 
and 0.12% PHMB-H mouthwash were shown to inhibit 
plaque re-growth and reduce oral bacterial counts [11, 
13]. However, both PHMB-H concentrations were less 
effective than 0.12% CHX positive control rinse. Fur-
ther studies support the ability of PHMB-H, at a higher 
concentration (0.2%), to diminish oral bacterial counts 
and prevent plaque re-growth, but this was significantly 
lower compared to CHX [14]. In vitro studies have con-
cluded that CHX-based mouthwashes presented bet-
ter anti-microbial activities against S. aureus than the 
PHMB-based mouthwash [19]. In contrast, it has been 
Figure 2 Anti-microbial activity of highly diluted PHMG-P (0.05%) and CHX (0.05%) against standard quality control microorganisms (S. aureus, E. 
coli, P. aeruginosa and C. albicans).
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reported that at 0.002% CHX did not eliminate P. gingi-
valis, A. actinomycetemcomitans, Fusobacterium nuclea-
tum, Tannerella forsythensis, Prevotella intermedia and 
Streptococcus anginosus after 1 min exposure time, unlike 
the anti-microbial effects 0.23% povidone-iodine (PVP-I) 
that eliminated bacteria after 15  s [17]. Müller claimed 
that polyhexamethylene bisguanide (PHMB) 7,000 mg/L 
had a stronger anti-bacterial efficacy than CHX 
100  mg/L, which in turn exceed PVP-I (7,000  mg/L), 
against S. aureus and E. coli [15].
In light of these apparent conflicts, the present study, 
showed both PHMG-P and CHX to have similar signifi-
cant anti-microbial activities against standard quality 
control microorganisms and periopathogens. A lack of 
rapid bactericidal of PHMG-P effect against S. mutans 
over 30 s was apparent and required an increased dura-
tion of exposure and repeated application to achieve the 
desired effect in the course of prophylactic or therapeu-
tic procedures. As opposed to 1% CHX, 1% PHMG-P 
did not exhibit bactericidal effects against L. acidophilus 
within 5  min of contact, which does not mean that the 
substance was inactive. PHMG-P gradually decreased L. 
acidophilus titers in a time and concentration dependent 
manner, however method sensitivity threshold was not 
reached.
Minimal concentrations of CHX decreased the amount 
of majority of bacteria (S. aureus, E. coli, P. aeruginosa, A. 
actinomycetemcomitans and P. gingivalis) to below detec-
tive limits of 0.2%, and increasing the concentration did 
not improve efficacy. For PHMG-P, such minimal effec-
tive concentration was 0.2% for E. coli and P. aeruginosa 
and 0.5% for S. aureus, A. actinomycetemcomitans and P. 
gingivalis. CHX expressed activity at lower concentra-
tions for 30  s against S. aureus, A. actinomycetemcomi-
tans and P. gingivalis, however the working concentration 
equals the minimal effective concentration (30  s) left a 
narrow therapeutic window for the antiseptics express 
their maximum effect before dilution in saliva.
Figure 3 Anti-microbial activity of clinical working concentrations of PHMG-P (1%) and CHX (0.2%) against perio- and cariogenic bacteria (P. gingi-
valis, A. actinomycetemcomitans, S. mutans and L. acidophilus).
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Studies in plant physiology, confirm that fructan, for 
example levan has a direct protective effect and capac-
ity to stabilize membranes during drying by insert-
ing part of the polysaccharide into the lipid headgroup 
region [20]. It is well-established that Lactobacilli pro-
duce a broad range of polymers, including levan- and 
inulin-type fructans and α-glucans (dextran, mutan and 
reuteran). Homo-polysaccharide and oligosaccharide 
production are most frequently found in L. acidophilus, 
L. johnsonii, L. mucosae, and L. reuteri [21]. Some spe-
cies of lactobacilli display an additional peptidoglycan 
outer paracrystalline layer of proteins (S-layer), which 
is a two-dimensional array of protein or glycoprotein 
subunits with stable tertiary structures ranging from 40 
to 60  kDa, highly basic, assembled in lattices with dif-
ferent symmetries that represent 10–15% of total cell 
wall proteins [21, 22]. Basic character of S-layer pro-
teins might influence the electrostatic interaction with 
cationic PHMG-P. This is accompanied by lack of bacte-
ricidal effect of PHMG-P on L. acidophilus. Perhaps, the 
decreased concentration of Lactobacilli in adults cannot 
be considered as an important factor in the prevention 
of dental caries, because 69% of tested Lactobacilli were 
reported to inhibit the growth of S. mutans, 88% of A. 
actinomycetemcomitans, 82% of P. gingivalis and 65% of 
Prevotella intermedia [23]. Despite the fact that PHMG-
P selectively acts against S. mutans and has no effect on 
L. acidophilus this biocide may be regarded as a preven-
tive remedy for dental caries.
According to our data, PHMG-P at concentration 
of 0.05% required 3  min to achieve bactericidal effects 
against the majority of bacteria. Thus, delayed bactericidal 
activity kinetics may be correlated with the three-dimen-
sional structure of PHMG-P. Literature reports, closely 
related PHMG-H, to possess seven types of molecular 
structures, including three linear types and four cyclic or 
Figure 4 Anti-microbial activity of highly diluted PHMG-P (0.05%) and CHX (0.05%) against perio- and cariogenic bacteria (P. gingivalis, A. actinomy-
cetemcomitans, S. mutans and L. acidophilus).
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branched ones, with an average coefficient of branching 
of 0.16–1.08 per molecule [24]. It has been established for 
PHMG-H that anti-microbial activity increased on a mass 
basis with elongated polymer chain length, high molecu-
lar weight materials with n >10 were highly effective.
Evaluation of bactericidal effect on different water-
soluble polymeric derivates of guanidine showed their 
good anti-microbial activity towards bacteria at low 
doses (13  mg/ml) [25]. They slightly damaged the outer 
membrane layer in cell envelope of E. coli and increased 
the permeability of the cytoplasmic membrane, whilst no 
significant damage was observed in the morphological 
structure of the cells. High doses (23 mg/ml) of PHMG-
H caused collapse of the outer membrane structure, 
generating local pores across the membrane and inflict-
ing severe lesions of the internal cell structure, leakage 
of intracellular components and cell inactivation [25]. 
PHMG-H containing disinfectant “Akwaton” displayed 
a sporicidal effect against suspended and fixed spores 
of Bacillus subtilis exposed for 1.5 min contact time 
≥0.44% (w/v) and 0.52% (w/v), respectively [26]. Akacid 
plus (consisting of a mixture (3:1) of PHMG-chloride and 
poly-[2-(2-ethoxy)-ethoxyethyl)-guanidinium-chloride]) 
removed S. aureus, Enterococcus hirae, E. coli, P. aer-
uginosa, C. albicans and Aspergillus niger at 0.1% within 
5  min [27]. PHMG-H based disinfectant displayed its 
germicidal function at very low concentrations, 0.005% 
(w/v) for E. coli and 0.04% (w/v) for MRSA, eliminating 
bacteria by 1.5 min [28].
Conclusion
The substance PHMG-P displayed anti-bacterial activity 
against standard quality control strains, periopathogens 
and S. mutans, even after a 20-fold dilution. The use of 
the antiseptic could have potential applications in the 
management of oral diseases, such as caries and peri-
odontal diseases.
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